CtBP1 (Phospho-Ser422) Antibody
- Known as:
- CtBP1 (Phospho-Ser422) Antibody
- Catalog number:
- 11796
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- CtBP1 (Phospho-Ser422) Antibody
Related genes to: CtBP1 (Phospho-Ser422) Antibody
- Gene:
- CTBP1 NIH gene
- Name:
- C-terminal binding protein 1
- Previous symbol:
- -
- Synonyms:
- BARS
- Chromosome:
- 4p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1997-08-22
- Date modifiied:
- 2016-10-05
Related products to: CtBP1 (Phospho-Ser422) Antibody
Related articles to: CtBP1 (Phospho-Ser422) Antibody
- Prostate cancer (PCa) ranks as the fifth most prevalent cancer type globally, with its incidence rising due to lifestyle changes. The prognosis significantly worsens at the metastatic stage, with a 5-year survival rate dropping to 30%. - Source: PubMed
Publication date: 2026/06/18
Pouresmaeili FarkhondehMohammadi MahanHosseini JalilAarabi AzadehFazeli ZahraTabatabaie Seyed Farhad Sadr - The C-terminal binding protein 1 (CTBP1) is a transcriptional corepressor with a major role in nervous system growth and development. There are only 20 published cases with mutations, displaying a phenotype of Hypotonia, Ataxia, Developmental Delay and Tooth enamel defect Syndrome (HADDTS). Histochemical evidence of decreased mitochondrial respiratory chain activity has been previously reported, but comprehensive data on the metabolic phenotype assessed by various cellular respiration parameters are still missing. We present a 10-year-old female with typical HADDTS features, harboring the most reported de novo heterozygous mutation c.991C>T. To elucidate her metabolic phenotype, we quantified mitochondrial respiration in peripheral blood mononuclear cells (PBMCs) utilizing an analyzer for assessing mitochondrial function (Seahorse XFp). Real-time metabolic assays revealed profound mitochondrial dysfunction with significantly attenuated maximal respiration and spare respiratory capacity compared to neurotypical controls. Following mitochondria-targeted nutritional support for one-year measurable bioenergetic improvements and reduced number of respiratory infections were registered. However, neurological recovery and new skill acquisition were not observed. We present a novel case of -related neurodevelopmental disorder and demonstrate, for the first time, the application of non-invasive, real-time mitochondrial functional assessment in this setting, providing additional evidence for mitochondrial dysfunction in HADDTS. - Source: PubMed
Publication date: 2026/04/29
Ivanov ZdravkoGevezova MariaPacheva IliyanaKetev KostadinChochkova-Bukova LyubovSarafian VictoriaIvanov Ivan - Metabolic dysfunction-associated steatotic liver disease (MASLD), marked by excess fat in the liver, has become the most prevalent chronic liver disease worldwide, affecting over 30% of adults. Its advanced form, metabolic dysfunction associated steatohepatitis (MASH), includes liver ballooning, and inflammation, and can progress to cirrhosis and hepatocellular carcinoma (HCC). Despite the increasing burden, effective pharmacotherapies for MASLD/MASH are still lacking. Programmed cell death mechanisms, such as autophagy and ferroptosis, are critical in the pathology of MASLD, influencing liver inflammation, fibrosis, and malignant transformation. This study employed six machine learning models—Random Forest, Logistic Regression, Extra Trees Classifier, Linear Discriminant Analysis, and Light Gradient Boosting Machine—to identify significant drug targets using Febuxostat, Perindopril, Amlodipine, and Atorvastatin, evaluated through molecular, biochemical, immunohistochemical, and pathological markers. We identified genes associated with MASH using microarray datasets from the Gene Expression Omnibus database, followed by protein-protein interaction and functional enrichment analyses to select genes related to ferroptosis, autophagy, and their epigenetic regulators (miRNAs-LncRNAs) in MASH-induced rats. Quantitative real-time PCR validated the expression of selected networks (mRNAs-miRNAs-LncRNAs). Additionally, we measured biochemical, inflammatory, and liver pathology markers to ensure the model’s robustness. Our results identified 16 out of 29 valuable therapeutic targets with an accuracy of 88.74% and an AUC of 0.9745, including LPCAT3, HGS, TSG101, SNF8, rno-miR-27a-5p, rno-miR-329-5p, CTBP1-AS2, ALT, AST, ALP, GGT, D. Bilirubin, Albumin, TMAO, GPX4, and TGFβ1. - Source: PubMed
Publication date: 2026/04/27
Matboli MarwaElanwar AlyKhaled RadwaKhaled AbdelrahmanEltantawy Eman Hamdy BadrHamam Ghada GalalAhmed Manar YehiaFouad ManarTarek Ahmed AsmaaElmasry MaryamEl-Shafei Marwa MAboulhoda Basma EmadDiab Gouda IbrahimAboughaleb Ibrahim H - Pathogenic variations in the PCLO gene cause Pontocerebellar Hypoplasia type 3 (PCH3), an extremely rare autosomal recessive disease characterized by seizure, intellectual disability, developmental delay, and microcephaly. PCLO encodes the Piccolo protein, which plays a critical role in synaptic function and neurological disorders. To date, only one pathogenic PCLO variant associated with PCH3 has been reported in the literature. While research on PCH3 is ongoing, the rarity of the condition has limited the number of studies. - Source: PubMed
Publication date: 2025/08/10
Baneshi MaryamMohammadi SedighehJafari Khamirani HosseinFallahi JafarDara MahintajTabei Fatemeh SadatRanjbar MaryamBagher Tabei Seyed Mohammad - Neonatal bilirubin encephalopathy (kernicterus) results from toxic accumulation of unconjugated bilirubin in the brain, often leading to irreversible neurological damage. Docosahexaenoic acid (DHA), an omega-3 fatty acid with anti-inflammatory and antioxidant properties, may attenuate bilirubin-induced neuropathological alterations in neonates. - Source: PubMed
Publication date: 2026/04/02
Yao YiZhang WenhongChi YunqianZhang ZihanWang YunheHao Wei